FIGURE 1 Schema: Shiga toxin interaction with eukaryotic cells.
Role of Shiga/Vero Toxins in Pathogenesis

ACTIVITIES OF Stx AND LPS IN RENAL DISEASE Shiga Toxin Actions
It is generally accepted that all actions of Shiga toxin (Stx) depend on its interaction with the receptor, globotriaosylceramide (Gb 3 ), on eukaryotic cells. Although alternative receptors for Stx have been postulated, no definitive data have been forthcoming in support. Stx holotoxin is internalized by receptor-mediated endocytosis, retrograde transported via the Golgi apparatus and processed through in the endoplasmic reticulum, and released into the cytoplasm where it enzymatically inactivates ribosomes and inhibits protein synthesis ( Fig. 1 ). However, it is important to note that, in addition to Stx holotoxin, the B-subunit alone can interact with Gb 3 in a physiologically meaningful manner where it activates signal transduction pathways in target cells ( Fig. 1) (1) . An additional but unexplained anomaly is the interaction of Stx with eukaryotic cells in a Gb 3 -independent manner that leads to induction of cytokines by these cells (2) . As shown in Fig. 1 , intracellular responses to Stx are diverse, including inhibition of protein synthesis, activation of cellular stress responses, and induction of cytokines and chemokines. It is likely that these different schemes take place in cell-specific activities during Shiga toxin-producing Escherichia coli (STEC) infections in humans, culminating in typical hemolytic-uremic syndrome (HUS). As depicted, it is clear that in some cases Stx can result in activation of p38 mitogen-activated protein kinase as well as apoptotic and necrotic cell death (Fig. 1) . The topic of HUS renal disease has been reviewed recently (3) (4) (5) .
Cell Types Responsive to Stx
The high number of Stx-sensitive cell types makes more difficult identification of more important events responsible for HUS. Renal microvascular endothelial cells are generally accepted to be the primary target of Stxs in HUS. Data in support of this concept come from many sources, most notably autopsy kidney pathology samples showing swollen and detached endothelial cells accompanied by thrombi (6) . Such human renal microvascular endothelial cells were also shown to be very sensitive to Stx in vitro (7) . However, other cells that make up the human renal glomerulus are also sensitive to Stx, including podocytes and mesangial cells (8, 9) . In addition, extraglomerular epithelial cell types of the human kidney have been postulated to be targets of Stx, including proximal tubule and collecting duct cells (8, 10, 11) . Cell types in the blood circulation that may be key to development of HUS and that are sensitive to Stx include platelets, neutrophils, and monocytes (12) (13) (14) (15) (16) .
In summary, most, if not all, of the cell types mentioned may well have a role in STEC-related kidney disease and typical HUS. The relative importance and role of these cell types in STEC HUS remain to be determined. For example, it is not clear which of the renal cell types are actually responsible for renal failure in STEC HUS, although apoptosis of tubules appears to be a common feature (8, 17) . The relative contributions in HUS disease of renal microvascular coagulation and thrombosis (i.e., endothelial cells), imbalance of fluid and electrolytes (i.e., nephron tubules), and altered filtration barrier function (i.e., endothelial and podocyte cells) have yet to be elucidated for typical HUS. If in vitro cell culture studies are pertinent to HUS in patients, the sensitivity (50% lethal dose) of human renal cells to Stx2 (endothelial, 0.1 pM > podocyte, 0.5 pM >> proximal tubule, 10 pM) suggests the renal filtration barrier is at considerable risk (8) .
Inflammatory Cells, Chemokines, and Renal Thrombosis
A primary feature in the renal pathology of STEC HUS is microvascular coagulation and thrombosis. In humans and in a murine model of HUS, the interaction of Stx and lipopolysaccharide (LPS) with circulating cells and resident renal cells appears to have a causal role in microvascular thrombosis (18, 19) . In a series of studies of the Stx/LPS murine model of HUS, a pathway leading to fibrin deposition was revealed ( Fig. 2 ). LPS activation of cells such as endothelial and renal tubule cells elicited chemokines (monocyte chemotactic protein 1 [MCP-1], macrophage inflammatory protein 1 [MIP-1] alpha, RANTES) known as chemoattractants for monocyte/macrophage cells and coactivators of platelets. In this response, Stx enhances the effects of but does not replace LPS. The response was associated with renal fibrin deposition (12, 20) . In the murine model, simultaneous neutralization of these three chemokines inhibited LPS/Stx-induced monocyte accumulation and fibrin deposition in the kidneys (20) . Further, administration of adenosine A2a receptor agonists to Stx/LPS mice also reduced monocyte and fibrin accumulation in the kidneys. As shown in Fig. 3 , adenosine A2a receptor agonists act as anti-inflammatory agents in monocytes, platelets, and endothelial cells (21) . Taken together, these studies indicate that both LPS and Stx are required for maximal renal fibrin deposition and that platelets may be required. Because mice deficient in MCP-1 have sharply reduced platelet deposition after exposure to Stx/LPS, we have suggested that this chemokine serves as a coactivator of platelets in typical HUS (Keepers TR, unpublished data). The primary activators of platelet activation are thrombin or adenosine diphosphate. Our renal gene array analysis of the LPS response in mice indicated that LPS strongly elicited fibrinogen mRNA, the precursor of fibrin (Obrig T, unpublished data). In addition, it is noteworthy that selective elimination of monocytes from mice prior to the above studies had no effect on the ability of Stx/LPS to elicit renal fibrin deposition, suggesting the chemokines are being generated from other cell types such as renal tubules (20) . Important conclusions from the murine HUS model are that LPS, not Stx, is the initial primary elicitor of renal coagulation and thrombosis, but Stx, not LPS, is the lethal agent of STEC.
In the murine Stx/LPS model of HUS, monocyte migration into the kidneys was restricted to the extraglomerular space in contrast to polymorphonuclear leukocytes (PMN), which, in addition, migrated into the glomeruli. The latter may be important in humans because neutrophilia has been implicated as a primary risk factor for HUS disease and increased neutrophil migration into the kidneys was a key observation in HUS renal biopsies (22, 23) . In the murine model of HUS, the neutrophil chemotactic factors chemokine ligand 1 (CXCL1) keratinocyte-derived chemokine (KC) and CXCL2 (MIP-2) were induced in the kidneys by LPS (15) . The induction was at the transcriptional level and was enhanced by Stx2. Administration of neutralizing antibodies for these neutrophil chemotactic factors prevented the movement of neutrophils into the kidneys. It was also demonstrated that vascular cell adhesion molecule 1 (VCAM-1) was induced in the kidneys simultaneously with CXCL-1 and CXCL-2 in response to Stx2/LPS in mice ( Fig. 4 ). VCAM-1 is known to assist movement of neutrophils across the endothelium and appeared to exhibit this function for neutrophils in the Stx2/LPS murine model of HUS. However, the relative importance of renal neutrophils in Stx-induced renal failure has yet to be determined in mice and humans.
Renal Gene Array Analysis of Murine Responses to Stx2 and LPS
Much information is now available regarding the biological effects of Stx2 and LPS on kidneys in the murine HUS model. The following is a synopsis of the more pertinent gene microarray data obtained from temporal studies of the murine renal responses to Stx2, LPS, or Stx2/LPS (19) . On the basis of the total of both upand downregulated genes, five times more renal genes responded to LPS than to Stx2 over the 72-h time course. Response to LPS was mostly early, whereas Stx2 responses occurred later in the 72-h time course. These results are more meaningful when viewed in the larger picture of HUS where renal failure occurs later in the time course in both mice and humans. It should be emphasized that Stx2, rather than LPS, is the lethal factor in the murine HUS model. The gene array data revealed different roles for LPS and Stx2 in the renal physiological responses. LPS responses were mostly inflammatory, stress related, or cell defensive in nature. In contrast, Stx2 responses were related to cell repair and involved cell proliferation and differentiation or cell cycle control genes. An interesting finding was that renal genes downregulated by Stx2 included membrane transporters, which appeared to signal a protective survival mode and slowing of cell metabolism.
The renal genes most upregulated by Stx2 or LPS are depicted in Fig. 5 . As expected from the inflammatory responses described above, LPS induced a number of chemokine genes that code for chemotactic factors for monocytes and neutrophils. These tend to be "immediate" response genes, which attract monocytes and neutrophils into the kidneys and set the stage for a broad inflammatory response in the kidneys. Such LPS "immediate" response genes are mentioned in the literature in descriptions of typical HUS, i.e., MCP-1, MIP-2alpha, and the murine interleukin-8 mimic, KC. It was also observed that interferon-gamma-inducible protein-10 (IP-10) (CXCL10) was induced by LPS and by Stx2, albeit in early and late parts of the HUS disease time course, respectively. Related to renal coagulation and thrombosis in HUS, LPS induced a set of fibrinogen genes "late" in the time course of the murine model of HUS concomitant with the appearance of fibrin deposition and coagulation in the renal microvasculature of HUS ( Fig. 5 ). These data agree with our observation that LPS is responsible, in part, for fibrin deposition in the Stx2/ LPS murine model of HUS (19) . Amyloid protein, which has been reported to be a Stx-sensitizing factor in HUS, is induced at the mRNA level by LPS in mice, as shown in Fig. 5 , as a renal "late" gene product (24) . More recently, complement has been identified as a factor that may contribute to renal failure in atypical HUS.
Products of some of the genes shown in Fig. 5 have been examined by investigators as potential biomarkers for diagnostic purposes. For example, IP-10 has been identified as a urine biomarker for other kidney diseases such as lupus nephritis (25, 26) . Lipocalin 2 (neutrophil gelatinase-associated lipocalin), an LPS-induced "early" 
How Valid Is the Murine Model of HUS for Translation to the Human Disease?
A large volume of data exists for mouse models of Stx-HUS (28) . The two common experimental approaches for these murine models are either oral infection with STEC or injection with purified Stx plus or minus LPS (17, 19, 29, 30) . In virtually all cases these are lethality models within 4 to 12 days after exposure to the agents and are accompanied by renal damage. Where examined, these murine models usually exhibit the three hallmarks of HUS: thrombocytopenia, hemolytic anemia, and renal failure. However, every animal model has its limitations, and for the murine models of HUS, the renal microvascular endothelial cells do not express Gb 3 and are resistant to Stx action. This is important if one believes that the primary target of Stx is the renal microvascular endothelium. Indeed, human renal endothelial cells in vitro are very sensitive to Stx, and the pathology of human kidneys in HUS describes swollen and detached glomerular endothelial cells. But it is surprising why such human glomerular endothelium is not killed by Stx in HUS kidneys. This suggests either a more indirect action of Stx in human HUS or dominant survival activities are activated within the endothelium after exposure to Stx. An alternative explanation is that the primary target of Stx in human kidneys is not the endothelium, but rather glomerular podocytes and extraglomerular tubules along the nephron. Support for this exists for HUS in mice and humans where urine specific gravity changes, chemokines are increased in the urine, and biomarkers of damaged podocytes and tubule cells are detected.
Mouse models have been helpful in separating the actions of Stx and LPS in HUS. In general, and as described above, LPS is the primary inducer of cytokines and chemokines where Stx enhances the activity of LPS. The complexity of inflammation in HUS is critical but has yet to be fully delineated in murine models and in human HUS. The murine model mirrors typical HUS of humans as resting platelets are resistant to Stx and require preactivation with LPS (19) . However, it is most important to reiterate that Stx, not LPS, is responsible for the renal failure in typical HUS. In conclusion, the murine responses to Stx and LPS include most of the features of STEC-HUS in humans.
ACTIVITIES OF Stx IN CNS DISEASE CNS Symptoms of Animal Models
In either an oral inoculation of STEC model or purified Stx injection animal model, the most common and most frequently reported central nervous system (CNS) impairment is paralysis of extremities. Most frequently, the hind legs are affected first, followed by the forelegs. Other symptoms include anorexia, lethargy, ataxic gait, recumbency (the affected animals lose strength to hold their body in an upright position), convulsions, seizure, coma, and death.
STEC oral administration animal models are summarized in Table 1 . The oral inoculation models of STEC that describe CNS symptoms are limited to pig and mouse. Pigs develop "edema disease" with Stx2eproducing E. coli and present CNS symptoms (Table 2) . Experimentally, the edema disease-like state is reproducible with Stx2-producing E. coli that has been isolated from human patients. CNS symptoms are only seen in Stx2 (both Stx2 and Stx2e) producers, but not in non-Stx2 producers. This indicates a strong association of Stx2 with CNS impairment.
LPS is an outer membrane component of gramnegative bacteria and a strong inflammation inducer. The involvement of LPS in STEC-associated CNS symptoms was tested by using LPS nonresponder mouse C3H/HeJ (29) . C3H/HeJ did present CNS symptoms when given Stx2-producing E. coli but not when Stxnonproducer was inoculated. This again suggests a strong involvement of Stx in CNS symptoms. The difference between LPS-responder mouse (C3H/HeN) and C3H/HeJ in CNS symptoms was that C3H/HeN showed a progressive time course of CNS symptoms whereas C3H/HeJ showed a "biphasic" response in that they developed milder CNS symptoms and recovered once, but then progressed to a severe form of CNS impairment. This suggests that even though Stx2 may be the central cause of CNS symptoms, addition of LPS response may contribute to the progress of the disease.
To further study the action of Stx2 in CNS disease, different animals were tested with purified Stx2. Stx2 injection animal models with CNS complications are summarized in Table 3 . Also, LPS involvement or contribution to Stx2-associated CNS disease was tested in some reports. The reproducible results of hind-leg paralysis and high frequency of convulsions and seizures with purified Stx confirm the central role of the toxin in STEC-associated CNS disease. Human STEC patients present CNS symptoms that range from eye involvement (diplopia, hallucinations, and cortical blindness), behavioral changes (hyperactivity, distractibility, irritability, and altered sensorium), posturing/coordination difficulties (poor fine-motor coordination, hemiplegia, ataxia, and clumsiness), to severe symptoms such as seizures, dysregulation of breathing, and alteration in consciousness such as coma. Within these varieties of symptoms, ataxia or hemiparesis resembles Stx-associated animal CNS symptoms. Also, it is notable that in human patients, seizures are a frequent observation. This resemblance between patients and animal models of STEC/Stx suggests there is a great possibility that analyzing these animal models may give some clues to define the mechanisms of CNS impairment in Stx-associated disease.
CNS Histopathology of Animal Models
In animal models with STEC oral inoculation that describe CNS symptoms, most exhibit defective capillaries (pig [31] [32] [33] [34] , mouse [35, 36] ). Those capillary lesions are mostly related to endothelial cell weakening that appears as hemorrhage, with leaked red blood cells in parenchyma. Noncapillary components in the parenchyma such as neurons and myelin defects were seen in some mouse STEC models (35, 37, 38) , but not others (36) . In purified Stx2 injection models, similar lesions involving capillary/endothelial cells were found in pig (39, 40) , rabbit (41) (42) (43) , and mouse (44, 45) . In contrast, other models did not have these lesions but rather lesions related to neuronal degeneration (baboon [46] , rabbit [43, 47, 48] , rat [49, 50] , mouse [51] ) or myelin degeneration (baboon [46] , rabbit [52] , rat [49] ). Also, some reports showed normal appearance of neurons (rabbit [47] , striatal neurons; mouse [53] lumbar spinal cord neurons). As all models exhibit similar CNS symptoms such as hind-leg paralysis, the difference in histopathological lesions may be due to involvement of different parts of CNS, different time points in the disease, or species-specific sensitivities. The mechanism of inducing CNS symptoms may be weakening of endothelial cells/ capillary composition-caused neurotoxicity or direct 
CNS Molecular Physiology of Animal Model
Molecular marker analysis in STEC or Stx animal models suggests possible mechanisms for Stx-associated CNS impairment. The apoptotic nature of Stx-associated lesions has been described. Terminal deoxynucleotidyltransferasemediated dUTP-biotin nick end labeling (TUNEL) stain detects fragmented DNA and therefore is often used as an apoptotic assay. Capillaries (pig [33] , rabbit [43, 54] ), neurons (mouse [55] , rabbit [43] ), and glial cells (rabbit [43] ) have been detected as TUNEL positive. Activated caspase-3 targeted immunohistochemistry has been used for another marker of apoptotic cells. Neurons (mouse [56] ) and capillaries (rabbit [54] ) have been detected positive. Another pro-apoptotic marker, bax, was found increased in rat neurons (57) . Along with electron microscopy observation (rat [49] ), some neurons and capillary cells (endothelial cells and pericytes) undergo apoptosis, but some appear as necrotic (rabbit [33] ). Careful and detailed information of which area of the CNS and what types of cells in that area present apoptotic features may help elucidate these conflicting results.
Aquaporin 4 (AQP4) is mostly expressed in astrocyte foot processes that have a direct contact with capillaries in the CNS. The reduction of AQP4 suggests that there is alteration in astrocytic foot process, which is important to strengthen the blood-brain barrier (BBB). AQP4 expression decreased in Stx2-injected rat (50) and STECinfected mouse (56) , while astrocytic activation marker glial fibrillary acidic protein increased. This suggests Stx-associated astrocyte activation may participate in weakening the BBB.
An increase in tumor necrosis factor alpha in STECinoculated mouse (37) and Stx2-injected rabbit (43) brain along with serum tumor necrosis factor alpha increase in STEC-inoculated rabbit (55) suggests Stxassociated inflammation in the CNS.
Ca 2+ imaging and electrophysiological study are useful tools to assess direct physiological action of Stx in fresh brain slices. Our group showed Stx2-associated neuronal glutamate release in mouse brain slice (cerebral cortex) indirectly by recording intracellular Ca 2+ in astrocyte (53) . Recently, it is shown that Stx2 induces depolarization of neurons in the thalamic area of female rat (58) .
Receptor Gb 3 Expression in Animal Central and Peripheral Nervous Systems (CNS, PNS)
Shiga toxin receptor localization in the animal nervous system has been described for different species. There are three ways to localize Shiga toxin receptor. First is to perform anti-Stx immunodetection in tissues of STECinfected or Stx-injected animals (rabbit [42, 47, 52] , rat [49, 59] , mouse [35, 36] ). Second is to incubate a naïve tissue section with Stx followed by anti-Stx immunodetection (pig [60] ). Third is to recognize Gb 3 as an Stx receptor with anti-Gb 3 immunodetection in tissues. Detecting anti-Gb 3 immunoreaction in the naïve tissue provides a basal expression level and cell types that would be influenced by Stx initially in the course of disease. These include neurons in the mouse spinal cord (53) and other regions of CNS (61) . In the Stxadministered tissue, it may or may not indicate the spontaneous Stx receptor expression but certainly indicates cell types responsive to Stx. The cell types that are positive in either of the analyses above often include small vessel endothelial cells (rabbit [42, 43, 47, 52, 62, 63] , mouse [45, 64] ), neurons (rat [49, 57, 59] , mouse [35, 45, 53, 61] ), and glial cells (rat [49, 57, 59] , mouse [45, 61] ). Miyatake and colleagues compared the peripheral nervous system (dorsal root ganglion) of different species with the same method and found that human and rabbit expressed Stx receptor in endothelial cells and neurons, whereas rat and mouse expression was restricted to neurons (62, 63) . Our group reported that throughout the mouse CNS, the only nonneuronal cell type to exhibit anti-Gb 3 immunoreactivity was the third ventricle ependymal cell (61) . Studies have suggested, in the naïve state, humans and rabbits express Stx receptor in their vessels as well as neurons, and rodents appear to express Gb 3 mainly in neurons. However, it was shown that Stx receptors in the rat CNS are induced by Stx administration (57) . Among different species, the receptor expression patterns in different regions of CNS, the cell types, and the amount expressed may be different, but all models present with common CNS impairment such as hind-leg paralysis. This may be interpreted as expression of Stx receptor in endothelial cells is not necessary for toxin to be able to internalize into the CNS parenchyma to have an effect.
In 2006, Okuda et al. (64) reported a 4galt knockout mouse that lacks Gb 3 synthase (alpha 1,4-galactosyltransferase) and therefore produces no Gb 3 . In this mouse, originally Gb 3 -positive vessels lost their anti-Gb 3 immunoreactivity and became Stx resistant. Gb 3 synthase probe has been applied for an in situ hybridization in the mouse (56) and rat (58) pathway enzymes such as Gb 3 synthase, a glycosyltransferase, add the terminal galactose to complete Gb 3 , other glycosyltransferases in the pathway are unique in each step of glycolipid synthesis, and there are catabolic pathway enzymes as well (see Fig. 6 ). All these enzymes participate in determining the amount of Gb 3 in the cell. Measuring these Gb 3 -associated enzymes may provide more insight into Stx receptor regulation.
Discussion about How Stx Enters CNS of Animals
Purified Stx peripheral injection (intraperitoneal [i.p.] or intravenous [i.v.]) is able to induce CNS impairment similar to that of STEC oral infection, suggesting that there is a direct effect of Stx on CNS parenchymal cells. The rat model of intraventricular purified Stx2 injection in which purified Stx2 is inoculated directly into CNS ND  ND  ND  ND  ND  ND  ND  ND  Yes  67  Baboon Stx1  Yes  ND  ND  ND  ND  ND  ND  3 parenchyma also induces similar CNS symptoms such as lethargy, hind-leg weakness, or paralysis (57) . These results suggest that Stx released from STEC internalizes into the blood and then transfers to CNS parenchyma and asserts its toxicity. The route and CNS region of Stx permeabilization are of great interest to explain which part of the CNS is most likely influenced by Stx. Stx injected by i.v. has been detected in cerebrospinal fluid (CSF) (rabbit [47, 65] ). This suggests there is translocation of Stx from blood to CSF. A reduction of AQP1 in choroid plexus in rat with Stx (i.p.) suggests that there is weakening of the blood-CSF barrier in this location that may allow Stx to enter CSF from the blood. The ependymal cells lining at the third ventricle are a border between CSF and CNS parenchyma. Our group showed in mouse CNS that ependymal cells at the third ventricle are expressing Gb 3 in a naïve state (61) . The tracer horseradish peroxidase that is injected intrathecally into CSF crossed and entered ependymal cells and parenchyma (rabbit [52] ), and magnetic resonance imaging showed the third ventricle area with a bright signal that is an indication of leakiness into the fluid in this area. Taken together, it is reasonable to think that Stx uses blood-CSF barrier penetration as one of the routes into CNS parenchyma. On the other hand, Stx injected i.p. was detected in the perivascular area in rat (49) , and BBB weakening was suggested by the reduction of AQP4 (rat [50] , mouse [56] , and by tracer horseradish peroxidase (i.v.) detection in parenchyma (mouse [35] ). These results suggest that Stx can also use the BBB crossing route to enter the CNS. An important fact to note is that purified Stx by itself, without any other bacterial component, can enter CNS and assert its toxicity regardless of differences in receptor-expressing cell types among different species. 
